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A B S T R A C T
Background: Population-based information on cancer incidence, prevalence and outcome are required to
inform clinical practice and research; but contemporary data are lacking for many myeloid malignancy
subtypes.
Methods: Set within a socio-demographically representative UK population of 4 million, myeloid
malignancy data (N = 5231 diagnoses) are from an established patient cohort. Information on incidence,
survival (relative & overall), transformation/progression, and prevalence is presented for >20 subtypes.
Results: The median diagnostic age was 72.4 years (InterQuartile Range 61.6–80.2), but there was
considerable subtype heterogeneity, particularly among the acute myeloid leukaemias (AML) where
medians ranged from 20.3 (IQR 13.9–43.8) for AML 11q23 through to 73.7 (IQR 57.3–79.1) for AML with no
recurrent genetic changes. Five-year Relative Survival (RS) estimates varied hugely; from <5% for
aggressive entities like therapy-related AML (2.6%, 95% Conﬁdence Interval 0.4–9.0) to >85% for indolent/
treatable conditions like chronic myeloid leukaemia (89.8%, 95% CI 84.0–93.6). With a couple of notable
exceptions, males experienced higher rates and worse survival than females: the age-standardized
incidence rates of several conditions was 2–4 higher in males than females, and the 5-year RS for all
subtypes combined was 48.8% (95% CI 46.5–51.2) and 60.4% (95% CI 57.7–62.9) for males and females
respectively. During follow-up (potential minimum 2 years and maximum 11 years) myelodysplastic
syndrome (MDS) progression to AML ranged from 25% for refractory anaemia with excess blasts through
to 5% for refractory anaemia with ring sideroblasts: the median interval between MDS and AML diagnosis
was 9.0 months (IQR 4.8–17.4 months).
Conclusions: The marked incidence and outcome variations seen by subtype, sex and age, conﬁrm the
requirement for “real-world” longitudinal data to inform aetiological hypotheses, healthcare planning,
and future monitoring of therapeutic change. Several challenges for routine cancer registration were
identiﬁed, including the need to link more effectively to diagnostic and clinical data sources, and to
review policies on the recording of progressions and transformations.
ã 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Accounting for around a third of all newly diagnosed
haematological malignancies, myeloid neoplasms (acute myeloid
leukaemias, myelodysplastic syndromes, and myeloproliferative
neoplasms) comprise a complex group of cancers with diverse* Corresponding author.
E-mail address: eve.roman@york.ac.uk (E. Roman).
http://dx.doi.org/10.1016/j.canep.2016.03.011
1877-7821/ã 2016 The Authors. Published by Elsevier Ltd. This is an open access articaetiologies, treatment pathways and outcomes [1,2]. Contempo-
rary population-based information about the occurrence and
outcome for many of these malignancies is however sparse, and for
some of the rarer cancer entities included within these categories
is largely non-existent. This absence of relevant data reﬂects the
paradigm changing nature of the new classiﬁcation systems
implemented over the last 15 years; the 2001 World Health
Organization (WHO) schema for tumours of the haematopoietic
and lymphoid tissue incorporating, for the ﬁrst time, genetic data
with information on morphology, immunology and clinicalle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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previously deﬁned categories, but also to the addition of several
new malignancies including, for example, the myelodysplastic
syndromes (MDS) which are still assigned a morphology behaviour
code of one and grouped with the ‘D codes’ in the latest update of
the site-based International Statistical Classiﬁcation of Diseases
(ICD-10) [4]. Such radical changes posed signiﬁcant problems for
population-based cancer registries; many struggling to capture all
haematological malignancies, particularly patients diagnosed with
MDS and chronic myeloproliferative neoplasms [5–7] and con-
tinuing to report using the traditional ICD-10 groupings of
leukaemia, Hodgkin lymphoma, non-Hodgkin lymphoma and
myeloma for a number of years [8–11].
In addition to the change in classiﬁcation and breadth of
investigations required to accurately diagnose haematological
malignancies (histology, cytology, immunophenotyping, cytoge-
netics, ﬂow cytometry and clinical data), a major factor impacting
on routine cancer registration is the fact that unlike other cancers
haematological malignancies are characterized by their ability to
progress and transform [1,2]. For example, certain MDS subtypes
are, by their nature, disposed to progress to AML and, in order to
deal with such phenomena, national and specialized cancer
registries have applied a range of different policies [12–15]. In
2010, the USA’s SEER (Surveillance, Epidemiology and End Results)
program issued guidelines to allow primary AML registrations in
patients with a prior MDS registration, unless the two diagnoses
were 21 days apart [15]; the 2001 guidelines, which prohibited
such registrations, having resulted in falling AML rates [16–18]. On
the other hand, ENCR (European Network of Cancer Registries) andTable 1
Total numbers of myeloid diagnoses and de Novo diagnoses: HMRN Sept 2004 to Aug 
Diagnoses 
Malignancy (International Classiﬁcation of Disease
for Oncology 3rd Edition)
Total Myeloid de novo (% 
All myeloid malignancies 5231 4945 (94.5) 
Acute myeloid leukaemia (AML) (9727, 9861, 9871,
9866, 9895, 9896, 9920)
1411 1190 (84.3) 
AML, not otherwise speciﬁed (9861) 860 825 (95.9) 
AML with myelodysplasia-related changes (9895) 197 13 (6.6) 
AML with NPM1 mutation (9861) 104 104 (100.0) 
Acute promyelocytic leukaemia (APL) (9866) 91 91 (100.0) 
AML, core binding factor (9871, 9896) 64 64 (100.0) 
AML, probable therapy related (9920) 61 59 (96.7) 
AML with MLL (11q23) (9897) 25 25 (100.0) 
Myelodysplastic syndromes (MDS) (9982–9986) 1194 1188 (99.5) 
Refractory cytopenia with multilineage
dysplasia (RCMD) (9985)
497 495 (99.6) 
Refractory anaemia with excess blasts (RAEB) (9983) 458 455 (99.3) 
Refractory anaemia with ring sideroblasts (RARS)
(9982)
213 212 (99.5) 
Myelodysplastic syndrome (5q-) (9986) 26 26 (100.0) 
Myeloproliferative neoplasms (MPN) (9741, 9875,
9950, 9961, 9962, 9964, 9975. 9875)
2330 2296 (98.5) 
Chronic MPNsa (9950, 9962, 9975) 1819 1812 (99.6) 
Chronic myeloid leukaemia (CML) (9875) 318 316 (99.4) 
Myeloﬁbrosis (9961) 165 140 (84.8) 
Systemic mastocytosis (9741) 26 26 (100.0) 
MDS/MPN (9945, 9946, 9975, 9876) 296 271 (91.6) 
Chronic myelomonocytic leukaemia (CMML) (9945) 239 221 (92.5) 
MDS/MPN, unclassiﬁable (9975) 30 24 (80.0) 
Atypical chronic myeloid leukaemia (9876) 23 22 (95.7) 
a Polycythaemia vera, essential thrombocythaemia, MPNs unclassiﬁed.European HAEMCARE guidelines state that only the ﬁrst tumour, in
this example MDS, should be counted in incidence statistics, unless
AML progression occurs within three months (90 days), in which
case the original MDS code should be replaced by the appropriate
AML code [13,14]. As well as variations in case deﬁnition, making
comparisons between the rates generated by different registries is
further complicated by the fact that standard populations with
widely differing age structures are often used for age-adjustment.
European registries have, for example, generally used the
1976 European standard [19–24], US SEER registries the US
2000 standard [16,17], and registries from elsewhere in the world
their own country speciﬁc standards and/or the 1996 World
standard [25–27].
Since 2001, continued advances in genomics and diagnostic
technologies have led to further WHO revisions, and haemato-
oncology continues to be one of the most rapidly evolving ﬁelds in
cancer research [1,2]. Accordingly, to address the need for
responsive “real-time” generalizable data on haematological
malignancies to inform contemporary clinical practice and
research, we established a population-based patient in cohort in
the UK in 2004–the Haematological Malignancy Research Network
(www.hmrn.org) [28]. Set within a catchment population of over
4 million people, all haematological malignancy diagnoses are
made and coded by clinical specialists working at a single
integrated haematopathology laboratory; and follow-up data are
collected to clinical trial standards. Providing up-to-date informa-
tion on patients diagnosed 2004–13 and followed through to
September 2015, the present report focuses on the occurrence
(incidence and prevalence) and outcomes (survival and2013.
Males Females
of total) Total Myeloid de novo (% of total) Total Myeloid de novo (% of total)
2868 2691 (93.8) 2363 2254 (95.4)
769 631 (82.1) 642 559 (87.1)
475 452 (95.2) 385 373 (96.9)
121 7 (5.8) 76 6 (7.9)
42 42 (100.0) 62 62 (100.0)
47 47 (100.0) 44 44 (100.0)
41 41 (100.0) 23 23 (100.0)
28 27 (96.4) 33 32 (97.0)
10 10 (100.0) 15 15 (100.0)
794 790 (99.5) 400 398 (99.5)
364 362 (99.5) 133 133 (100.0)
291 290 (99.7) 167 165 (98.8)
135 134 (99.3) 78 78 (100.0)
4 4 (100.0) 22 22 (100.0)
1118 1100 (98.4) 1212 1196 (98.7)
820 815 (99.4) 999 997 (99.8)
189 188 (99.5) 129 128 (99.2)
99 87 (87.9) 66 53 (80.3)
8 8 (100.0) 18 18 (100.0)
187 170 (90.9) 109 101 (92.7)
152 140 (92.1) 87 81 (93.1)
17 13 (76.5) 13 11 (84.6)
17 16 (94.1) 6 6 (100.0)
Table 2
Median ages (Inter Quartile Range-IQR) of patients diagnosed with myeloid malignancies: HMRN 2004 to Aug 2013.
All patients Males Females
Total N =5231 Myeloid de novo N=4945 Total N =2879 Myeloid de novo N=2691 Total N =2378 Myeloid de novo N=2254
All myeloid malignancies 72.4 (61.6–80.2) 72.5 (61.3–80.4) 72.0 (61.8–79.6) 72.1 (61.5–79.8) 72.7 (61.2–81.1) 72.9 (60.9–81.4)
Acute myeloid leukaemia(AML) 70.6 (57.3–79.1) 70.9 (55.4–79.6) 69.8 (57.4–78.2) 69.8(55.3–78.4) 71.2 (57.2–80.4) 71.7 (56.5–81.0)
AML, not otherwise speciﬁed 73.7 (62.4–81.5) 73.7 (62.3–81.7) 72.4 (61.7–79.9) 72.4(61.5–80.0) 75.8 (64.3–84.0) 75.8 (64.0–84.0)
AML with myelodysplasia-related changes 70.0 (63.4–75.5) 77.0 (72.2–78.2) 70.1 (63.6–75.3) 75.1(72.2–78.0) 69.9 (62.4–76.8) 77.6 (73.5–78.6)
AML with NPM1 mutation 72.0 (57.3–79.0) 72.0 (57.6–79.0) 70.6 (50.3–79.5) 70.6(50.3–79.5) 72.3 (60.0–78.9) 72.3 (60.0–78.9)
Acute promyelocytic leukaemia(APL) 47.2 (33.1–63.1) 47.2 (33.1–63.1) 48.0 (33.1–63.1) 48.0(33.1–63.1) 47.1 (32.8–60.9) 47.1 (32.8–60.9)
AML, core binding factor 42.9 (27.6–56.9) 41.8(28.4–57.2) 44.3(24.6–54.6)
AML, probable therapy related 71.9 (59.7–77.4) 72.4 (59.5–78.4) 72.6 (67.7–76.6) 72.7(66.8–77.4) 68.6 (58.6–78.4) 67.5(58.6–78.5)
AML with MLL(11q23) 20.3 (13.9–43.8) 29.2(13.9–44.6) 20.3(13.2–39.4)
Myelodysplastic syndromes(MDS) 75.7 (68.5–81.7) 75.7(68.5–81.7) 75.7(68.5–81.4) 75.8(68.6–81.4) 75.6(68.5–82.6) 75.7(68.5–82.6)
Refractory cytopenia with multilineage dysplasia (RCMD) 75.7 (69.3–81.5) 75.7(69.3–81.5) 75.7(69.4–81.2) 75.7(69.6–81.2) 75.9(68.5–82.5)
Refractory anaemia with excess blasts (RAEB) 74.5 (66.7–81.3) 74.6(66.8–81.5) 74.9(67.2–81.0) 75.0(67.4–81.0) 73.6(65.9–81.9) 74.2(65.9–81.9)
Refractory anaemia with ring sideroblasts (RARS) 77.6 (71.4–83.5) 77.5(71.4–83.5) 76.9(69.6–83.0) 76.9(69.6–82.3) 78.9(72.1–83.7) 78.9(72.1–83.7)
Myelodysplastic syndrome (5q-) 72.0(61.7–78.0) 78.6(70.2–84.0) 69.6(61.4–77.3)
Myeloproliferative neoplasms (MPN) 70.3(58.5–79.2) 70.2(58.4–79.2) 68.2(57.6–77.8) 68.1(57.6–77.8) 71.7(59.9–80.4) 71.7(59.7–80.3)
Chronic MPNsa 71.4(60.7–79.9) 71.4(60.6–79.9) 69.7(60.0–78.8) 69.6(59.8–78.8) 72.5(61.7–81.1) 72.5(61.7–81.1)
Chronic myeloid leukaemia (CML) 59.1(46.8–71.1) 59.1(46.8–71.1) 57.7(46.7–69.5) 57.8(46.7–69.5) 61.3(47.7–73.1) 61.2(47.3–73.0)
Myeloﬁbrosis 73.7(65.7–79.8) 74.1(65.3–80.0) 72.0(63.4–79.0) 72.8(63.4–79.1) 75.4(68.4–81.9) 75.6(68.4–81.9)
Systemic mastocytosis 59.3(37.6–69.2) 70.6(66.2–72.2) 48.3(34.6–59.9)
MDS/MPN 77.2(69.4–82.8) 77.4(70.7–83.1) 76.3(69.4–82.0) 76.4(69.4–82.4) 77.8(70.0–83.5) 78.4(71.6–84.2)
Chronic myelomonocytic leukaemia 77.4(71.5–82.9) 77.4(71.6–83.1) 76.4(69.9–82.0) 76.4(71.3–82.1) 78.4(72.5–83.5) 78.9(73.4–84.2)
MDS/MPN, unclassiﬁable 77.5(67.6–82.9) 78.4(71.3–84.1) 77.2(67.6–82.4) 78.4(71.7–82.9) 77.7(68.0–85.0) 78.4(71.0–86.4)
Atypical chronic myeloid leukaemia 71.4(66.7–81.8) 72.0(66.7–81.8) 71.4(68.2–81.8) 73.2(67.8–82.5) 68.1(55.3–79.8)
a Polycythaemia vera, essential thrombocythaemia, MPNs unclassiﬁed.
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E. Roman et al. / Cancer Epidemiology 42 (2016) 186–198 189transformations/progressions) across the full spectrum of myeloid
neoplasms.
2. Methods
Data are from the UK’s population-based Haematological
Malignancy Research Network (www.hmrn.org) which, with a
catchment population of nearly 4 million people, has a socio-
demographic composition that broadly mirrors that of the UK as a
whole [29]. Initiated in 2004, full details of its structure, data
collection methods and ethical approvals have been previously
described [28]. Brieﬂy, within HMRN patient care is provided by
14 hospitals organized into ﬁve multi-disciplinary teams (MDTs);
and clinical practice adheres to national guidelines. As a matter of
policy, all diagnoses, including progressions and transformations,
are reported and coded by clinical haematopathology specialists at
the Haematological Malignancy Diagnostic Service (www.hmds.
info); this requirement occurs irrespective of the patient’s age,
treatment intent, or management within the National Health
Service (NHS) or private sector. HMDS, which is cited in the UK’s
Department of Health guidance documents as the model for
service delivery [30,31], is a fully integrated facility; bringing
together the relevant technology and expertise required for the
diagnosis and on-going monitoring of all haematological malig-
nancies. With respect to myeloid malignancies, the diagnosis of
most remains centred on morphological assessment of the bone
marrow; the subsequent integration of diagnostic characteristics
with clinical features, in particular blood count parameters,
enabling accurate diagnosis and subclassiﬁcation. Importantly,
within HMDS all bone marrows are dual reported to ensure
accuracy, and a number of additional technologies are employed to
conﬁrm the diagnosis and reﬁne classiﬁcation, including cytoge-
netics and ﬂow cytometry.
HMRN’s cohort has Section 251 support under the NHS Act
2006, and all patients have prognostic, treatment, response andFig.1. Age at diagnosis box and whisker plots by diagnostic group; acute myeloid leukaem
and MDS/MPN: Haematological Malignancy Research Network diagnosed 2004–2013.outcome data collected to clinical trial standards; and all are
‘ﬂagged’ and followed-up for death and subsequent cancer
registrations at the national Medical Research Information Service
(MRIS). For analytical purposes, area-based population counts are
routinely sourced from the Ofﬁce of National Statistics [32]. In the
present report, all analyses were conducted either in the statistical
package Stata 13 [33] or R [34]. Incidence rates and their 95%
Conﬁdence Intervals (CIs) were estimated by Poisson regression.
Directly age-standardized rates were calculated using the Stata
command ‘dstdize’ and corresponding age standardized sex rate
ratios and their 95% conﬁdence intervals were estimated [35].
Overall survival was calculated using standard time to event
analyses and the program strel (v1.2.7) was used to estimate
relative survival; age and sex-speciﬁc background mortality rates
were obtained from national life tables [36]. Prevalence estimates
(3-, 5- and 10-year) and corresponding conﬁdence intervals were
calculated from incidence and survival data using R’s ‘survival’ and
‘rms’ libraries; 3 and 5 year estimates were calculated directly from
the patient cohort, and Monte-Carlo simulation techniques were
employed to generate the larger 10-year values [37].
3. Results
Of the 5231 myeloid malignancies diagnosed September
2004 to August 2013, 4945 (94.5%) were new diagnoses (de novo)
falling within one of the four main WHO diagnostic categories of
acute myeloid leukaemia (AML), myelodysplastic syndromes
(MDS), myeloproliferative neoplasms (MPN) and MDS/MPN; and
286 (5.5%) were secondary, following a previous diagnosis in
another myeloid category. These data are distributed by gender and
subtype (for those with more than 20 diagnoses) in Table 1. As
expected, the largest difference between the total diagnostic series
and the myeloid de novo series was seen for acute myeloid
leukaemia (AML) with myelodysplasia related changes; 184
(93.4%) of the 197 diagnoses following a preceding myeloidias (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN)
Table 3
Crude and age standardized incidence rates per 100,000 (95% conﬁdence interval): HMRN Sept 2004 to Aug 2013.
Crude European 2013 European 1976 USA 2001 World 1996
All myeloid malignancies 16.28 (15.84–16.72) 19.06 (18.89–19.23) 12.41 (12.29–12.52) 13.64 (13.51–13.76) 8.76 (8.58–8.67)
Acute myeloid leukaemia 4.39 (4.16–4.63) 5.06 (4.97–5.15) 3.48 (3.41–3.54) 3.75 (3.69–3.82) 2.58 (2.52–2.63)
AML-not otherwise speciﬁed 2.68 (2.50–2.86) 3.13 (3.06–3.20) 2.00 (1.95–2.05) 2.24 (2.19–2.29) 1.41 (1.37–1.46)
AML with myelodysplasia-related changes 0.61 (0.53–0.70) 0.73 (0.69–0.76) 0.49 (0.46–0.52) 0.50 (0.48–0.53) 0.35 (0.32–0.37)
AML with NPM mutation 0.32 (0.26–0.39) 0.37 (0.34–0.40) 0.25 (0.23–0.28) 0.28 (0.25–0.30) 0.18 (0.16–0.20)
Acute promyelocytic leukaemia 0.28 (0.23–0.35) 0.30 (0.27–0.33) 0.27 (0.25–0.30) 0.27 (0.25–0.30) 0.24 (0.21–0.27)
AML, core binding factor 0.20 (0.15–0.25) 0.20 (0.18–0.23) 0.20 (0.17–0.22) 0.20 (0.17–0.22) 0.18 (0.16–0.21)
AML, probable therapy related 0.19 (0.15–0.24) 0.22 (0.20–0.25) 0.15 (0.13–0.17) 0.16 (0.14–0.18) 0.11 (0.09–0.12)
AML with MLL(11q23) 0.08 (0.05–0.11) 0.07 (0.05–0.09) 0.09 (0.06–0.11) 0.08 (0.06–0.10) 0.10 (0.07–0.12)
Myelodysplastic syndromes (MDS) 3.72 (3.51–3.93) 4.44 (4.35–4.52) 2.58 (2.53–2.64) 3.01 (2.95–3.07) 1.67 (1.63–1.71)
Refractory cytopenia with multilineage dysplasia 1.55 (1.41–1.69) 1.85 (1.80–1.91) 1.07 (1.03–1.10) 1.25 (1.21–1.29) 0.68 (0.65–0.70)
Refractory anaemia with excess blasts 1.43 (1.30–1.56) 1.69 (1.64–1.74) 1.02 (0.98–1.06) 1.16 (1.12–1.20) 0.68 (0.65–0.71)
Refractory anaemia with ring sideroblasts 0.66 (0.58–0.76) 0.79 (0.76–0.83) 0.43 (0.41–0.46) 0.53 (0.50–0.56) 0.27 (0.25–0.28)
MDS (5q-) 0.08 (0.05–0.12) 0.10 (0.07–0.12) 0.06 (0.05–0.08) 0.07 (0.05–0.08) 0.04 (0.03–0.05)
Myeloproliferative neoplasms (MPN) 7.25 (6.96–7.55) 8.47 (8.35–8.58) 5.73 (5.64–5.81) 6.13 (6.05–6.22) 4.02 (3.96–4.09)
Chronic MPNs 5.66 (5.40–5.93) 6.65 (6.55–6.76) 4.37 (4.30–4.44) 4.74 (4.66–4.81) 3.02 (2.97–3.07)
Chronic myeloid leukaemia 0.99 (0.88–1.10) 1.10 (1.06–1.14) 0.89 (0.86–0.93) 0.90 (0.86–0.93) 0.69 (0.66–0.72)
Myeloﬁbrosis 0.51 (0.44–0.60) 0.61 (0.58–0.65) 0.38 (0.35–0.40) 0.42 (0.39–0.44) 0.25 (0.23–0.27)
Systemic mastocytosis 0.08 (0.05–0.12) 0.09 (0.06–0.12) 0.08 (0.05–0.10) 0.07 (0.05–0.09) 0.06 (0.04–0.08)
MDS/MPN 0.92 (0.82–1.03) 1.10 (1.06–1.15) 0.62 (0.59–0.65) 0.74 (0.71–0.78) 0.40 (0.38–0.43)
Chronic myelomonocytic leukaemia 0.74 (0.65–0.84) 0.89 (0.85–0.93) 0.49 (0.46–0.52) 0.60 (0.57–0.63) 0.30(0.28–0.32)
MDS/MPN, unclassiﬁed 0.09 (0.06–0.13) 0.11 (0.09–0.14) 0.06 (0.05–0.08) 0.07 (0.06–0.09) 0.04 (0.03–0.05)
Atypical chronic myeloid leukaemia 0.07 (0.05–0.11) 0.09 (0.07–0.11) 0.05 (0.04–0.07) 0.06 (0.04–0.07) 0.04 (0.03–0.05)
Males
All myeloid malignancies 18.42 (17.75–19.11) 25.14 (24.82–25.45) 15.63 (15.44–15.83) 17.7 (17.7–17.92) 10.76 (10.48–10.62)
Acute myeloid leukaemia 4.94 (4.60–5.30) 6.50 (6.34–6.66) 4.29 (4.19–4.40) 4.74 (4.62–4.86) 3.11 (3.02–3.20)
AML-not otherwise speciﬁed 3.05 (2.78–3.34) 4.17 (4.04–4.30) 2.60 (2.51–2.69) 2.95 (2.86–3.05) 1.80 (1.73–1.88)
AML with myelodysplasia-related changes 0.78 (0.64–0.93) 1.02 (0.95–1.10) 0.67 (0.61–0.72) 0.70 (0.64–0.76) 0.46 (0.42–0.50)
AML with NPM mutation 0.27 (0.19–0.36) 0.35 (0.28–0.42) 0.23 (0.18–0.28) 0.27 (0.21–0.32) 0.16 (0.12–0.20)
Acute promyelocytic leukaemia 0.30 (0.22–0.40) 0.32 (0.26–0.38) 0.29 (0.24–0.34) 0.29 (0.24–0.34) 0.25 (0.20–0.30)
AML, core binding factor 0.26 (0.19–0.36) 0.28 (0.22–0.34) 0.26 (0.21–0.31) 0.26 (0.21–0.32) 0.24 (0.18–0.29)
AML, probable therapy related 0.18 (0.12–0.26) 0.25 (0.19–0.30) 0.15 (0.11–0.19) 0.26 (0.21–0.32) 0.10 (0.7–0.14)
AML with MLL(11q23) 0.06 (0.03–0.12) 0.06 (0.03–0.09) 0.07 (0.03–0.11) 0.17 (0.13–0.21) 0.08 (0.03–0.12)
Myelodysplastic syndromes (MDS) 5.10 (4.75–5.47) 7.41 (7.24–7.59) 4.10 (4.00–4.20) 4.98 (4.86–5.10) 2.55 (2.48–2.62)
Refractory cytopenia with multilineage dysplasia 2.34 (2.10–2.59) 3.41 (3.29–3.53) 1.87 (1.80–1.94) 2.28 (2.20–2.36) 1.15 (1.11–1.20)
Refractory anaemia with excess blasts 1.87 (1.66–2.10) 2.68 (2.57–2.79) 1.52 (1.46–1.59) 1.82 (1.74–1.89) 0.97 (0.92–1.01)
Refractory anaemia with ring sideroblasts 0.87 (0.73–1.03) 1.28 (1.21–1.36) 0.69 (0.64–0.73) 0.86 (0.80–0.91) 0.42 (0.39–0.45)
MDS (5q-) 0.03 (0.01–0.07) 0.04 (0.01–0.07) 0.02 (0.00–0.04) 0.03 (0.00–0.05) 0.01 (0.00–0.02)
Myeloproliferative neoplasms (MPN) 7.18 (6.77–7.61) 9.45 (9.26–9.64) 6.28 (6.16–6.41) 6.79 (6.65–6.92) 4.37 (4.28–4.46)
Chronic MPNs 5.27 (4.91–5.64) 7.08 (6.91–7.25) 4.55 (4.45–4.66) 4.99 (4.87–5.11) 3.10 (3.02–3.19)
Chronic myeloid leukaemia 1.21 (1.05–1.40) 1.41 (1.33–1.49) 1.14 (1.07–1.20) 1.15 (1.08–1.21) 0.87 (0.82–0.93)
Myeloﬁbrosis 0.64 (0.52–0.77) 0.88 (0.81–0.95) 0.54 (0.49–0.58) 0.59 (0.54–0.64) 0.35 (0.32–0.38)
Systemic mastocytosis 0.05 (0.02–0.10) 0.06 (0.03–0.10) 0.04 (0.02–0.07) 0.04 (0.02–0.07) 0.03 (0.01–0.05)
MDS/MPN 1.20 (1.04–1.39) 1.78 (1.69–1.88) 0.96 (0.90–1.02) 1.19 (1.12–1.26) 0.59 (0.54–0.64)
Chronic myelomonocytic leukaemia 0.98 (0.83–1.14) 1.45 (1.37–1.54) 0.77 (0.72–0.83) 0.97 (0.91–1.03) 0.47 (0.43–0.50)
MDS/MPN, unclassiﬁed 0.11 (0.06–0.17) 0.16 (0.11–0.21) 0.09 (0.06–0.12) 0.11 (0.07–0.14) 0.05 (0.03–0.07)
Atypical chronic myeloid leukaemia 0.11 (0.06–0.17) 0.16 (0.11–0.21) 0.09 (0.06–0.12) 0.10 (0.07–0.13) 0.06 (0.04–0.08)
Females
All myeloid malignancies 14.26 (13.69–14.85) 15.07 (14.87–15.28) 10.10 (9.95–10.25) 10.96 (10.81–11.11) 7.33 (7.09–7.21)
Acute myeloid leukaemia 3.87 (3.58–4.19) 4.07 (3.96–4.18) 2.86 (2.78–2.95) 2.16 (2.08–2.23) 3.06 (2.98–3.15)
AML-not otherwise speciﬁed 2.32 (2.10–2.57) 2.41 (2.32–2.50) 1.55 (1.48–1.62) 1.74 (1.67–1.81) 1.10 (1.04–1.16)
AML with myelodysplasia-related changes 0.46 (0.36–0.57) 0.51 (0.45–0.56) 0.36 (0.31–0.40) 0.36 (0.31–0.40) 0.26 (0.21–0.30)
AML with NPM mutation 0.37 (0.29–0.48) 0.40 (0.35–0.46) 0.28 (0.23–0.32) 0.29 (0.25–0.34) 0.20 (0.16–0.24)
Acute promyelocytic leukaemia 0.27 (0.19–0.36) 0.28 (0.23–0.33) 0.26 (0.22–0.31) 0.26 (0.21–0.31) 0.23 (0.18–0.27)
AML, core binding factor 0.14 (0.09–0.21) 0.14 (0.10–0.19) 0.14 (0.10–0.18) 0.14 (0.10–0.18) 0.13 (0.09–0.18)
AML, probable therapy related 0.20 (0.14–0.28) 0.22 (0.18–0.26) 0.16 (0.13–0.19) 0.16 (0.12–0.19) 0.11 (0.08–0.14)
AML with MLL(11q23) 0.09 (0.05–0.15) 0.09 (0.05–0.12) 0.10 (0.06–0.14) 0.10 (0.06–0.14) 0.12 (0.07–0.16)
Myelodysplastic syndromes (MDS) 2.41 (2.18–2.66) 2.53 (2.44–2.62) 1.54 (1.48–1.61) 1.75 (1.68–1.82) 1.04 (0.98–1.10)
Refractory cytopenia with multilineage dysplasia 0.80 (0.67–0.95) 0.85 (0.79–0.90) 0.51 (0.47–0.55) 0.58 (0.54–0.62) 0.33 (0.30–0.37)
Refractory anaemia with excess blasts 1.01 (0.86–1.17) 1.06 (0.99–1.13) 0.68 (0.62–0.73) 0.75 (0.69–0.80) 0.48 (0.42–0.53)
Refractory anaemia with ring sideroblasts 0.47 (0.37–0.59) 0.48 (0.43–0.52) 0.26 (0.23–0.29) 0.32 (0.29–0.35) 0.16 (0.14–0.18)
MDS (5q-) 0.13 (0.08–0.20) 0.15 (0.11–0.19) 0.10 (0.07–0.13) 0.10 (0.07–0.13) 0.07 (0.05–0.09)
Myeloproliferative neoplasms (MPN) 7.31 (6.91–7.74) 7.79 (7.64–7.94) 5.30 (5.19–5.41) 5.68 (5.57–5.79) 3.75 (3.67–3.84)
Chronic MPNs 6.03 (5.66–6.41) 6.42 (6.28–6.55) 4.27 (4.17–4.36) 4.61 (4.51–4.71) 2.98 (2.90–3.05)
Chronic myeloid leukaemia 0.78 (0.65–0.93) 0.83 (0.78–0.89) 0.67 (0.62–0.72) 0.68 (0.63–0.73) 0.52 (0.48–0.57)
Myeloﬁbrosis 0.40 (0.31–0.51) 0.42 (0.37–0.47) 0.25 (0.22–0.29) 0.29 (0.25–0.32) 0.16 (0.14–0.19)
Systemic mastocytosis 0.11 (0.06–0.17) 0.12 (0.08–0.16) 0.11 (0.07–0.15) 0.10 (0.07–0.14) 0.09 (0.06–0.12)
MDS/MPN 0.66 (0.54–0.79) 0.68 (0.62–0.73) 0.40 (0.35–0.44) 0.47 (0.42–0.51) 0.27 (0.23–0.31)
Chronic myelomonocytic leukaemia 0.53 (0.42–0.65) 0.54 (0.49–0.59) 0.29 (0.26–0.33) 0.36 (0.32–0.40) 0.18 (0.16–0.21)
MDS/MPN, unclassiﬁable 0.08 (0.04–0.13) 0.08 (0.05–0.11) 0.05 (0.03–0.07) 0.05 (0.03–0.08) 0.03 (0.02–0.04)
Atypical chronic myeloid leukaemia 0.04 (0.01–0.08) 0.04 (0.01–0.07) 0.03 (0.00–0.05) 0.03 (0.01–0.05) 0.02 (0.00–0.04)
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Fig. 2. Age-standardized (European 2013) sex rate-ratios by diagnostic group; acute myeloid leukaemias (AML), myelodysplastic syndromes (MDS), myeloproliferative
neoplasms (MPN) and MDS/MPN: Haematological Malignancy Research Network diagnosed 2004–2013.
E. Roman et al. / Cancer Epidemiology 42 (2016) 186–198 191malignancy. MDS accounted for 167 (90.8%) of the 184 prior
diagnoses the median diagnostic interval between MDS and AML
being 9.0 months (InterQuartile Range 4.8–17.4 months).
As with many other cancers, the likelihood of developing a
myeloid malignancy increased markedly with increasing age
(Table 2); the median age at diagnosis of all 5231 myeloid subtypes
combined being 72.4 years (IQR 61.5–80.2 years) and, with
relatively few exceptions, the patterns among males and females
were broadly similar. However, as can be seen more clearly in the
box and whiskers plots shown in Fig. 1, there is considerable
variation both between and within the four WHO major groupings
of AML, MDS, MPN, and MDS/MPN. This is particularly evident for
AML (shown in red in Fig. 1), where the median diagnostic age
ranged from 20.3 years (IQR 13.9–43.8 years) for patients
diagnosed with AML that had an 11q23 rearrangement (N = 25)
through to 73.7 years (IQR 62.3–81.7 years) for the larger group of
patients that had AML with no recurrent genetic changes and was
not therapy-related (N = 860). For most subtypes, the median
diagnostic ages of those diagnosed with de novo disease was
broadly comparable to that of the totality (Table 2).
The impact of the choice of standard population is clearly
evident in Table 3, which shows the crude rates together with the
age-adjusted rates calculated by applying our 5-year age-speciﬁc
rates to four commonly used hypothetical standard populations
(direct standardization). As might be expected, the new 2013 Eu-
ropean Standard Population (ESP), which has the greatest
weighting towards older ages, yielded age-adjusted summary
rates that were closest to our own crude rates. By comparison,
those produced using the 1996 world standard, the population
with the greatest weighting towards younger groups, are
approximately half the size. Furthermore, whilst those resulting
from the widely used USA 2001 and European 1976 standards aremore closely aligned, the older age distribution of the USA
2001 standard nonetheless yields rates that are consistently higher
than those produced by the 1976 European standard.
In general, with a couple of notable exceptions, myeloid
malignancies tend to occur far more frequently in males than
females. These gender differences are plainly visible in Fig. 2, which
shows the age-standardized (European 2013) sex-speciﬁc rate ratios
(malerate/female rate)orderedby magnitudewithin each of the four
main subtype groupings.As withage, there isvariation both between
and within the main diagnostic groups, the range for MDS being
particularly marked; female patients having a signiﬁcant predomi-
nance among those diagnosed with MDS that had an isolated 5q
deletion (MDS 5q-; male rate/female rate = 0.27, 95% Conﬁdence
Interval 0.14–0.51) and males predominating in all other subtypes,
the rate ratio for those with refractory cytopenia with multilineage
dysplasia being the highest at 4.02 (95% CI 3.73–4.32).
Prevalence estimates (3-, 5-, and 10-year) based on all data are
presented in Table 4. Data for 4 subtypes (MDS 5q-, systemic
mastocytosis, MDS/MPN unclassiﬁed, and atypical CML) are not
presented because of small numbers. For all myeloid malignancies,
the combined prevalence ranged from 34.3 per 100,000 (95% CI
32.4–36.3 per 100,000) within 3 years of diagnosis, through to
50.0 per 100,000 (95% CI 47.7–52.4 per 100,000) within 5 years and
79.2 per 100,000 (95% CI 86.2–82.2 per 100,000) within 10 years.
For some conditions, such as APL, the prevalent pools will contain
individuals who have been cured of their cancer; the proportion
increasing as time from diagnosis increases. For others, particularly
the MPNs where the 3-, 5- and 10-year estimates per 100,000 are
21.7 (95% CI 20.2- 23.3), 33.2 (95% 31.3–35.0) and 56.8 (95% CI 54.2–
59.3) respectively, the prevalent pools will contain individuals who
are either being actively monitored or who are receiving treatment
for their disease.
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192 E. Roman et al. / Cancer Epidemiology 42 (2016) 186–198The aggressive nature of most myeloid malignancies is
evident from the 5-year overall and relative survival (RS)
estimates shown in Table 5, and the corresponding 3-year
relative survival curves in Fig. 3; both Table and the Figure being
based on all 5231 diagnoses. With a 5-year RS of only 14.7% (95%
CI 12.9–16.7%), patients diagnosed with AML fared the worst;
the RS curve falling steeply within the ﬁrst few months of
diagnosis (Fig. 3a). Within the AML group there is, however,
considerable variation by subtype; therapy-related AML and
AML with myelodysplasia related changes being almost
universally and rapidly fatal, whereas patients diagnosed with
acute promyelocytic leukaemia (APL) or AML with core-binding
factor mutations were more likely than not to survive for 5 years
or more (Table 5); the relative survival curves of both of these
subtypes falling steeply within the ﬁrst 3 months but levelling
off thereafter (Fig. 3b).
Overall, whilst outcomes for patients diagnosed with MDS
are marginally better than those for patients diagnosed with
AML (Fig. 3a), the 5-year RS of the MDS patient group as a whole,
is only 28.1% (95% CI 24.9–31.5%) (Table 3). Furthermore, as with
AML there is considerable heterogeneity across the various MDS
entities (Fig. 3c), patients diagnosed with MDS 5q- faring
considerably better (5-year RS = 68.7%; 95% CI 35.6–87.3%) than
those with refractory anaemia and excess blasts (RAEB, 5-year
RS = 9.9; 95% CI 6.9–13.6%). It is important to remember,
however, that patients diagnosed with MDS that progressed
to AML during the 9-year study period are currently counted in
both Fig. 3b and c. The impact of this is illustrated more clearly
in Fig. 4 where, in-line with mortality, the follow-up period for
progression to AML has been extended by two years to
September 2015. In total, 199 (16.6%) of the 1193 patients
diagnosed with MDS between September 2004 and August
2013 had a subsequent diagnosis of AML before 1st September
2015. As expected, patients with RAEB were the most likely to
progress; 116 (25%) of the 458 patients diagnosed with RAEB
having a subsequent diagnosis of AML, the median time to
progression being 9.3 months (IQR 4.5–19.4 months). Patients
diagnosed with refractory cytopenia with multilineage dyspla-
sia (RCMB) also exhibited comparatively high levels of
progression; 13.9% (69/496) having a subsequent AML diagno-
sis, albeit over a longer time-frame (median time to
progression = 15.2 months, IQR 6.9–33.6 months). In addition,
although less impactful in terms of absolute numbers of
diagnoses, patients with MDS 5q- and refractory anaemia with
ring sideroblasts (RARS) also contributed to the both groups: the
respective progression frequencies being 11.5% (n = 3/26;
median time to progression = 31.8 months) and 5.2% (n = 11/
213; median time to progression = 10.9 months). Finally, the
progression free survival curves shown in Fig. 4b, conﬁrm the
generally poor outcomes for patients with all four MDS
subtypes.
In stark contrast to other myeloid groups, the mortality
experience of patients diagnosed with MPNs approached that of
the general population (5-year RS 89.3%; 95% CI 86.9–91.3); the
most favourable outcomes being seen for patients with chronic
MPNs (5-year RS 93.1%, 95% CI 90.2–95.1%). JAK2 mutations have
been used to diagnose all chronic MPNs within the study region
since 2005; but the classiﬁcation into the main component
subtypes of polycythaemia vera (PV), essential thrombocythae-
mia (ET) and MPNs unclassiﬁed, which requires access to blood
count and other clinical parameters, has not been routinely
applied. However, as part of a clinical audit we assembled
population-based information for a 60 month period (Sept
2006-Aug 2009, Sept 2011-Aug 2013), and the incidence rates
per 100,000 (crude and age-adjusted) and 5-year OS and RS
estimates are shown in Table 6. With a Standardized (European
Table 5
Five-year overall survival (OS) and relative survival (RS) estimates (95% conﬁdence interval) for myeloid malignancies: Haematological Malignancy Research Network
diagnoses Sept 2004 to Aug 2013, followed through to September 2015.
Total diagnoses Males Females
OS (95% CI) RS (95% CI) OS (95% CI) RS (95% CI) OS (95% CI) RS (95% CI)
All myeloid malignancies 40.3 (38.9–41.7) 51.2 (49.5–52.9) 38 (36.0–40.0) 48.8 (46.3–51.2) 48.2 (45.9–50.4) 60.4 (57.7–62.9)
Acute myeloid leukaemia 12.9 (11.3–14.7) 14.7 (12.9–16.7) 12.8 (10.6–15.2) 14.7 (12.2–17.4) 13.3 (10.9–15.9) 14.9 (12.3–17.9)
AML, not otherwise speciﬁed 8.2 (6.6–10.0) 9.5 (7.7–11.7) 8.8 (6.5–11.4) 10.2 (7.6–13.3) 7.4 (5.2–9.9) 8.7 (6.2–11.7)
AML with myelodysplasia-related changes 2.8 (1.3–5.4) 3.1 (1.4–5.9) 1.8 (0.5–4.6) 2.0 (0.6–5.0) 4.6 (1.6–10.4) 4.9 (1.6–11.1)
AML with NPM mutation 22.2 (14.5–30.9) 25.0 (16.3–34.6) 25.3 (13.1–39.4) 29.0 (14.8–44.8) 21.0 (11.8–32.0) 23.4 (13.1–35.5)
Acute promyelocytic leukaemia 58.6 (47.0–68.4) 61.7 (49.4–71.9) 55.3 (38.8–69.0) 59.7 (41.4–74.0) 61.4 (44.5–74.6) 62.9 (45.4–76.2)
AML, core binding factor 55.3 (42.0–66.7) 57.1 (43.3–68.7) 50.0 (33.5–64.3) 51.2 (34.3–65.8) 64.3 (41.2–80.3) 66.8 (42.2–82.8)
AML, probable therapy related 2.4 (0.4–8.3) 2.6 (0.4–9.0) 5.2 (0.9–15.5) 5.80 (1.0–17.0) 1.1 (0.0–8.9) 1.2 (0.0–9.2)
AML with MLL (11q23) 31.1 (14.0–50.0) 31.4 (14.1–50.4) 46.7 (16.0–72.9) 47.1 (16.0–73.4) 22.8 (5.9–46.3) 22.9 (5.9–46.5)
Myelodysplastic syndromes (MDS) 21.2 (18.7–23.8) 28.1 (24.9–31.5) 19.2 (16.2–22.4) 25.5 (21.5–29.7) 24.8 (20.3–29.6) 32.0 (26.1–37.9)
Refractory cytopenia with multilineage dysplasia 23.1 (19.1–27.3) 31.1 (25.7–36.6) 21.2 (16.6–26.2) 28.4 (22.2–35.0) 27.3 (19.3–36) 36.4 (25.6–47.2)
Refractory anaemia with excess blasts 7.9 (5.5–10.9) 9.9 (6.9–13.6) 7.6 (4.5–11.8) 9.8 (5.7–15.1) 8.4 (4.6–13.8) 10.2 (5.5–16.6)
Refractory anaemia with ring sideroblasts 41.3 (34.2–48.3) 57.2 (47.1–66) 37.5 (28.6–46.3) 51.6 (39–62.8) 47.8 (35.0–59.5) 62.8 (45.0–76.2)
Myelodysplastic syndrome(5q-) 53.7 (31.6–71.4) 68.7 (35.6–87.3) 23.8 (0.8–65.5) 29.4 (0.6–74.7) 56.4 (31.1–75.5) 72.5 (31.9–91.4)
Myeloproliferative neoplasms (MPN) 69.7 (67.7–71.7) 89.3 (86.9–91.3) 68.0 (64.8–70.9) 87.6 (83.8–90.5) 73.2 (70.3–75.9) 92.8 (89.4–95.2)
Chronic MPNsb 71.5 (69.2–73.7) 93.1 (90.2–95.1) 70.0 (66.3–73.3) 93.9 (88.5–96.8) 73.8 (70.6–76.7) 94.3 (90.2–96.7)
Chronic myeloid leukaemia 77.7 (72.3–82.2) 89.8 (84.0–93.6) 78.3 (71.0–84.0) 88.7 (80.4–93.6) 77.0 (67.6–84.0) 92.1 (78.4–97.2)
Myeloﬁbrosis 32.1 (24.2–40.2) 42.0 (31.5–52.1) 25.7 (16.3–36.3) 32.8 (20.5–45.7) 44.9 (28.3–60.2) 59.7 (35.8–77.1)
Systemic mastocytosis 79.8 (57.9–91.1) 88.7 (53.2–97.8) 59.5 (19.8–84.7) 62.9 (19.1–87.8) 87.9 (59.5–96.9) 95.5 (10.8–99.9)
MDS/MPN 13.0 (9.1–17.6) 17.4 (12.1–23.5) 9.4 (5.1–15.3) 12.6 (6.8–20.2) 19.7 (11.2–29.9) 26.8 (15.1–39.9)
Chronic myelomonocytic leukaemia 13.3 (9.1–18.4) 18.1 (12.3–24.8) 10.6 (5.7–17.4) 14.3 (7.5–23.1) 19.5 (10.6–30.5) 27.0 (14.4–41.3)
MDS/MPN, unclassiﬁedb 0 0 0 0 0 0
Atypical chronic myeloid leukaemia 0.2 (0.0–11.0) 0.2 (0.0–12.5) 0.1 (0.0–8.1) 0.1 (0.0–9.2) 17.4 (1.1–50.6) 18.5 (1.1–53.0)
aPolycythaemia vera, essential thrombocythaemia, MPNs unclassiﬁed.
b All 23 patients died within 5 years of diagnosis.
E. Roman et al. / Cancer Epidemiology 42 (2016) 186–198 1932013) Incidence Rate of 4.35 (95%CI 4.2–4.5) per 100,000 ET is the
commonest of the chronic MPNs, and those that were not further
classiﬁable the rarest (SIR 0.79, 95%CI 0.72–0.87). The sex-rate
ratios of ET (1.06) and PV (1.05) were similar, and 5-year RS
estimates of both were over 90% (Table 6). By contrast, patients in
the unclassiﬁable category had worse survival (5-year RS 75.9%;
95%CI 61.64–85.47%) and were more likely to be male (sex-rate
ratio 1.94, 95%CI 1.58–2.37).
With a 5-year RS of only 42.0% (95% CI 31.5–52.1%), the
165 patients diagnosed with myeloﬁbrosis stand apart from those
with other MPNs (Fig. 3d). The survival of the comparatively small
number of patients (n = 296) diagnosed with MDS/MPN disorders
was uniformly poor (Table 5); the 5-year RS of the group as a whole
being only 17.4% (95% CI 12.1–23.5%), with all three identiﬁed
subtypes faring equally badly (Fig. 4e).
Lastly, within our population-based series the outcomes for
females diagnosed with a myeloid malignancy tended to be
marginally better than those of males (Table 5): the 5-year RS for
all subtypes combined being 60.4% (95% CI 57.7–62.9%) and 48.8%
(95% CI 46.3–51.2%) respectively (P < 0.001). Across MDS and MPN
subtypes, this gender disparity appears to be of a fairly general
nature, the 5-year RS estimates of all subtypes being lower for
males than females, albeit not statistically signiﬁcantly so. There is
more heterogeneity amongst AML subtypes, most notably for AML
with MLL (11q23) where the 5-year RS were 47.1% (16.0–72.9%) and
22.9% (5.9–46.5%) for males and females respectively. Interestingly
AML (11q23) does not have a male predominance (Fig. 2), and
onsets at a much younger age than other AML subtypes (Table 2).
4. Discussion
This paper presents ‘real-world’ contemporary data on inci-
dence, prevalence, progression/transformation and survival across
the myeloid malignancy spectrum; providing new information to
inform aetiological hypotheses and plan health-care services, aswell as supplying a much needed baseline from which to monitor
the impact of future therapeutic changes. Our longitudinal
approach enabled us to examine occurrence and outcome (death
and progression) frequencies in the general patient population for
the four main myeloid entities (AML, MDS, MPN and MDS/MPN), as
well as for 18 constituent WHO deﬁned subtypes. Our analyses not
only evidenced the heterogeneity of this complex cancer group, but
also uncovered a number of novel ﬁndings. For example, with
respect to gender, our age-standardized rate-based analysis
revealed much larger incidence differences between males and
females than is generally thought to be the case [1], and our
relative survival analysis showed that, in contrast to lymphoid
subtypes [38], for most myeloid subtypes, outcomes for males are
generally worse for males than females. In addition, our
longitudinal examination of progressions and transformations,
which explored the challenges such events present for routine
cancer registration, highlighted key variations in policy that are
currently impacting on national occurrence and survival estimates.
Major strengths of our study include its large well-deﬁned
population-based catchment area, completeness of case ascer-
tainment, detailed follow-up and world-class diagnostics; all of
which combine to ensure that HMRN’s patient cohort is not
affected by the data quality issues commonly faced by many
population-based cancer registries [5–17,19,26,27]. With respect to
diagnosis, as one of the largest integrated haematopathology
laboratories in Europe the Haematological Malignancy Diagnostic
Service (HMDS), which lies at the centre of HMRN, has a strong
track-record of national/international research and diagnostic
policy adheres to European guidelines (www.hmds.info). In accord
with WHO and European recommendations [2,39,40], bone
marrow evaluation is a mandatory requirement for all MDS and
AML diagnoses, including transformations and progressions, and
ﬂow cytometry immunophenotyping is a core feature of the
diagnostic pathway, along with cytogenetics and molecular
studies. Nonetheless HMDS is subject to some of the same
Fig. 3. 3-year relative survival estimates a) main diagnostic group; b) acute myeloid leukaemias (AML); c) myelodysplastic syndromes (MDS); d) myeloproliferative
neoplasms (MPN); e) MDS/MPN: Haematological Malignancy Research Network diagnosed 2004–2013.
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Fig. 4. Myelodysplastic Syndromes (MDS) a) free from progression to AML b) progression free survival: Haematological Malignancy Research Network diagnoses Sept 2004 to
Aug 2013, followed through to Feb 2015.
E. Roman et al. / Cancer Epidemiology 42 (2016) 186–198 195limitations as other diagnostic laboratories. The heavy reliance on
morphology, for example, particularly in relation to the diagnosis
of MDS, remains a problem due to poor inter-observer concordance
and the numerous non-neoplastic conditions that can mimic MDS
[41,42]. For this reason, within HMDS patients with refractory
cytopenia with unilineage dysplasia (RCUD) are not assigned a
WHO ICD-O3 code at this point in their pathway, instead they are
ﬂagged for close clinical monitoring. The frequency of AML with
myelodysplasia related changes is also likely to be an underesti-
mate since HMDS only include patients with a previous or
concurrent myelodysplastic diagnoses, and not those with poor
cytogenetics.
Further diagnostic challenges are present for those categories
that generally require access to clinical data as well as sample
material. For example, in the sub-classiﬁcation of therapy related
myeloid conditions currently clinical data are only incorporated
at HMDS for AML. In the future, however, additional information
about preceding and succeeding cancers will be obtained via
linkage to nationally compiled cancer registration and hospital
episode statistics (HES); permitting a more in-depth analyses of
second cancers and therapy related disorders across all haema-
tological malignancy subtypes (myeloid and lymphoid). Likewise,
at HMDS JAK2 mutations are used to diagnose chronic MPNs; but
the further breakdown into polycythaemia vera (PV) and essential
thrombocythaemia (ET) requires access to blood count data and
other clinical parameters, and these procedures have only
recently been routinely incorporated. Reliable data on chronic
MPNs are, however sparse and the ﬁve years of incidence data
presented in the present report, which lie towards the top end of
the published ranges, add to the body of knowledge on this topic
[43,44].Weighting to a common standard population is required in
order to make incidence comparisons within and between
populations; and because registries tend to use different standards
we applied our rates to three commonly used hypothetical
populations (European 1976, USA 2001, and World 1996), as well
as to the new 2013 European standard which is set to form the
basis of future European health care statistics. With respect to UK
national reference comparisons, data are only published for AML
(all subtypes combined) and CML; and in this context it is
important to note that our age standardized (European 1976)
incidence rates of 3.48 per 100,000 for AML and 0.89 per 100,000
CML are closely aligned to the similarly standardized rates of
3.40 and 0.89 per 100,000 reported for England as a whole [22]. In
the USA, in addition to data on AML and CML, SEER publish
population-based incidence estimates for chronic myelomonocytic
leukaemia (CMML), and chronic myleoproliferative neoplasms, as
well as MDS (all subtypes combined). With respect to CMML and
chronic MPNs, our USA 2001 standardized rates of 0.60 and
4.74 per 100,000 are signiﬁcantly higher than those reported by
SEER; their 2010 rates being 0.42 and 2.61 per 100,000 respectively.
For chronic MPNs (polycythaemia vera, essential thombocythemia
and MPN-unclassiﬁed) the difference is most likely due to the
comparatively benign nature of these diseases and the consequent
failure to capture all diagnoses within SEER [45,46], whereas for
CMML misscategorization to CML is the more likely cause [1]. For
MDS, however, SEER’s 2010 overall rate of 5.31 per 100,000 (http://
seer.cancer.gov/faststats/) is greater than our equivalently stan-
dardized (USA 2001) rate of 3.07 per 100,000. This difference
largely reﬂects the fact that instead of assigning a ﬁnal diagnosis of
refractory cytopenia with unilineage dysplasia (RCUD), which in
specialist European MDS registries accounts for around 10–20% of
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196 E. Roman et al. / Cancer Epidemiology 42 (2016) 186–198MDS diagnoses [1,20,21,47–49], HMDS report these patients and
ﬂag them for follow-up. Furthermore, in contrast to many other
registries the fully integrated nature of HMDS’s reporting system
means that the category “MDS not otherwise speciﬁed (NOS)” is
neither used nor needed; and so our rates for the more clearly
deﬁned MDS subtypes of refractory cytopenia with multilineage
dysplasia (RCMD), refractory anaemia with excess blasts (RAEB),
refectory anaemia with ring sideroblasts (RARS), and MDS 5q- tend
to be higher than those produced by MDS registries that obtain
data from multiple sources [6,20,21,27,48,50].
With respect to progression and transformation frequencies,
the levels documented thus far during our follow-up period
(minimum 2 years, maximum 11 years) are broadly in line with
those reported by other specialist registries [1,2,51]: MDS to AML
progression ranging, for example, from 25% for RAEB and 14%
RCMD, through to 12% for MDS 5q- and 5% for RARS. Unfortunately
as with the use of standard populations, the policies applied by
population-based cancer registries to document progressions and
transformations differ one from another; and such variations
impact on the incidence and survival statistics produced. The
European Network of Cancer Registry (ENCR) guidelines state, for
example, that if AML is diagnosed within 90 days (3 months) of an
initial MDS diagnosis, the MDS diagnosis should be changed to
AML and no record of the transformation need be kept; but if AML
is diagnosed after 90 days the transformation should, if possible, be
noted but only the MDS should be counted in incidence estimates
[14]. In our data, 171 (86.0%) of the 199 MDS to AML trans-
formations (diagnosed 09/04 to 08/13, followed-up to 09/15)
occurred after 90 days (our maximum interval was 8.1 years;
median 11.5 months); and so under ENCR guidelines these AMLs
would not be counted. However, in contrast to ENCR, SEER’s
guidelines specify that unless the diagnoses of MDS and AML
are  21 days apart (our minimum interval was 32 days) both
should be counted in incidence estimates [15]. Hence, our
approach is basically similar to SEER’s and that used in a Swedish
analysis of AML cancer registration data [12], and accords with
WHO’s coding rules which assign AML patients with a previous
MDS diagnosis to the “AML with myelodysplasia-related changes”
category [1].
Contemporary real-world population-based information on the
survival of patients diagnosed with myeloid malignancies are
exceedingly sparse since, as with incidence, data on the categories
deﬁned in WHO’s 2001 diagnostic revision have only been
published for some AML subtypes [12,52–54], some MDS subtypes
[21,51,53,54], and CML [23,53–57]. Hence our comprehensive up-
to-date analysis of WHO deﬁned subtypes is a major contribution
to the literature which, as far as we can tell, has not been replicated
elsewhere. Importantly such information provides the context for
interpretation of data from clinical trials, as well as the baseline
against which to evaluate the impact of new therapeutic advances
across the patient population as a whole [58]. Furthermore, the fact
that our subtype survival estimates are broadly consistent with
those that have been published on by others [12,21,23,51,52],
provides further evidence [59] that patients diagnosed with
haematological malignancies in the UK do not suffer from the
survival inequalities commonly reported for cancers, such as
breast, colorectum and lung [60].
With respect to gender differences, our analyses not only
conﬁrm the large, but so far unexplained, fact that compared to
females males are at signiﬁcantly increased risk of developing
most myeloid subtypes, but also highlighted consistent disparities
in survival: the 5-year relative survival for all myeloid malignan-
cies combined being signiﬁcantly lower in males (48.8%; 95% CI
46.3–51.2) than females (60.4%; 95% CI 57.7–62.9). With respect to
incidence, the consistency of the male excess, which reached four-
fold for RCMD and atypical CML, is striking; and also serve to
E. Roman et al. / Cancer Epidemiology 42 (2016) 186–198 197highlight subtypes that failed to exhibit such differences. In this
regard, with its well-known distinct female excess [1,51] yielding a
sex-rate ratio of 0.3 (95% 0.1–0.5) in our data, MDS 5q- stands apart
from other MDS subtypes. Interestingly, within our patient cohort
incidence rates of most lymphoid subtypes are also signiﬁcantly
higher among males than females although, in contrast to the
myeloid malignancies reported on here, no differences in outcome
were evident [38].
In summary, our contemporary longitudinal analysis of “real-
world” population-based data on myeloid malignancies categor-
ised by WHO subtype demonstrated marked incidence and
survival variations by subtype, age and sex; providing valuable
base-line information not only for researchers, clinicians and
patients, but also for service commissioners and regulators. In
addition, we also identiﬁed some key challenges for routine cancer
registration; the lack of concordance on the recording of
progressions/transformations, which impacts on both incidence
and survival estimates, being one such issue deserving the
attention of policy makers.
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